STELLATE UNILATERAL NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS: A MULTIMODAL IMAGING ANALYSIS AND CASE REPORT.

PURPOSE: To describe a case of stellate nonhereditary idiopathic foveomacular retinoschisis in a middle-aged woman and to depict the classic retinal fluorangiography (FA) findings, structural characteristics using macular spectral-domain optical coherence tomography angiographic data of vascular and perfusion density using optical coherence tomography angiography (OCT-A), and standardized multifocal electroretinography (mfERG) findings. METHODS: This is a case report of a 53-year-old ophthalmologist who was incidentally diagnosed with unilateral idiopathic foveomacular retinoschisis. Stellate nonhereditary idiopathic foveomacular retinoschisis is defined as a foveal elevation without alternative explanation for retinoschisis. FA, spectral-domain optical coherence tomography, optical coherence tomography angiography, and multifocal electroretinography were used as tools to obtain an integral multimodal diagnosis of this entity. RESULTS: Clinical examination and multimodal imaging were able to detect unilateral idiopathic retinoschisis, revealing a stellate pattern of retinal concentric cysts with minimal changes in vascular and perfusion density metrics and confirming the absence of bridging vessels. There were consistent FA findings, with almost unaltered foveal changes. Multifocal electroretinography depicted a subtle reduction in dark-adapted a-wave and b-wave amplitudes. CONCLUSION: Improvements and innovations in technology for ophthalmic diagnosis have revolutionized our capacity for diagnostic decision-making. Spectral-domain optical coherence tomography and optical coherence tomography angiography are useful tools for diagnosis and follow-up assessment. This fortuitous case gives a window on the importance of a routine specialized ophthalmic examination and how multimodal imaging can depict important and specific findings not evident from a clinical point of view. The subtle but important changes observed in optical coherence tomography angiography and multifocal electroretinography will help better define this clinical entity.

Metabolic control and diabetic retinopathy.

The Early Treatment Diabetic Retinopathy Study (ETDRS) identified important risk factors for progression to high risk proliferative diabetic retinopathy (PDR) including retinopathy severity, decreased visual acuity, and high levels of hemoglobin A1C (HbA1c). Additional risk factors for progression to PDR are decreased hematocrit and increased serum lipids. The long-term benefit of improving glycemic control was evaluated by three large studies: the Diabetes Control and Complications Trial (DCCT), the Stockholm Interventional Study, and the UK prospective study. Several small studies, notably the Kuwamoto study, also evaluated the relationship between the glycemic control and diabetic retinopathy. Intensive glycemic control reduces the risk of any retinopathy by approximately 27%. Intensive therapy is most effective when initiated early in the course of the diabetes, demonstrating a beneficial effect over the course and progression of retinopathy. The long term benefits of the intensive glycemic control greatly outweigh the risk of "early worsening." Lowering elevated serum lipid levels has been shown to decrease the risk of cardiovascular morbidity. The ETDRS data suggest that lipid lowering may also decrease the risk of hard exudate formation and associated vision loss in patients with diabetic retinopathy. Preservation of vision may be an additional motivating factor for lowering serum lipid levels in persons with diabetic retinopathy and elevated serum lipid levels.

Diabetic retinopathy and angiogenesis.

Diabetic retinopathy, a secondary microvascular complication of diabetes mellitus is the leading cause of blindness in the Unites States amongst individuals age 20 to 64. Two major retinal problems cause most of the diabetes-related vision loss: diabetic macular edema and complications from abnormal retinal blood vessel growth, angiogenesis. Secondary to angiogenesis, increased retinal blood flow is of pathogenic importance in the progression of diabetic retinopathy. Understanding the role of hyperglycemia seems to be the most critical factor in regulating retinal blood flow, as increased levels of blood glucose are thought to have a structural and physiological effect on retinal capillaries causing them to be both functionally and anatomically incompetent. High blood glucose induces hypoxia in retinal tissues, thus leading to the production of VEGF-A (vascular endothelial growth factor protein). Hypoxia is a key regulator of VEGF-induced ocular neovascularization. Secondary to the induction of VEGF by hypoxia, angiogenesis can be controlled by angiogenic inducers and inhibitors. The balance between VEGF and angiogenic inhibitors may determine the proliferation of angiogenesis in diabetic retinopathy. Since VEGF-A is a powerful angiogenic inducer, utilizing anti-VEGF treatments has proved to be a successful protocol in the treatment of proliferative diabetic retinopathy.

Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks.

PURPOSE: To evaluate the visual and anatomical outcomes of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) treatment of choroidal neovascularization (CNV) in patients with angioid streaks (ASs). METHODS: A 44-year-old man with angioid streaks and CNV in both eyes (best-corrected visual acuity: 20/400, right eye; 20/50, left eye) received intravitreal bevacizumab injections at monthly intervals. RESULTS: Best-corrected visual acuity in the right eye after 2 intravitreal injections of bevacizumab was 20/70 and remained the same at the 6-month follow-up. Best-corrected visual acuity in the left eye after 3 intravitreal injections of bevacizumab was 20/25 and remained the same at the 9-month follow-up. CONCLUSIONS: After intravitreal administration of bevacizumab, our patient had visual acuity improvement in both eyes that was associated with rapid and significant reduction in thickness, subretinal fluid, and size of subfoveal neovascularization secondary to ASs. Intravitreal bevacizumab treatment resulted in a meaningful and sustained vision gain after the 9-months follow-up.

Intravitreal triamcinolone for the treatment of diabetic macular edema.

Diabetic macular edema is one of the leading causes of visual loss in first world countries and the first cause in diabetic retinopathy. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. Nevertheless, progressive visual loss is found in the 26% of patients with diabetic macular edema treated with photocoagulation. The failure of laser treatment and the destructive nature of the therapy has forced researchers to pursue new alternatives including vitrectomy with or without internal limiting membrane peels, the use of proteinkinase C inhibitors, intravitreal injections of antibodies that inhibit the vascular endothelial growth factor, somatostatin analog, or the intravitreal injection with corticosteroids. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Publications evaluating the safety and efficacy of intravitreal injection of triamcinolone in the treatment of diabetic macular edema show varying outcomes with respect to the increases of visual acuity and decreases in foveal thickness. Despite this, intravitreal triamcinolone is a treatment that has evolved quickly and is considered increasingly useful.

Anti-macular degeneration agents.

Anti-VEGF therapy is a promising new avenue for the treatment of ocular neovascular diseases. Early preclinical data and recent clinical data support the efficacy and safety of several novel anti-VEGF for NVAMD. Whether these novel biologics are used on their own, in combination with previously available therapies, or with newly developing therapies, they represent a new avenue in treatment. These agents are highly selective in their targeted approaches, and when administered appropriately , offer treatment with minimal damage to retinal tissue. In the future, biotherapeutic agents will certainly play a powerful role in the treatment of human choroidal neovascular membrane formation.

Fishing-related ocular trauma.

PURPOSE: To evaluate the characteristics of fishing-related ocular injuries. DESIGN: Retrospective observational analysis of a computerized databank. METHODS: The United States Eye Injury Registry was used to analyze 143 patients with fishing-related ocular injury. Epidemiologic and clinical information was evaluated including the age and gender of the subjects, classification of ocular trauma, surgical management, and final visual acuity. RESULTS: Of the 732 cases of sport-related ocular trauma, 143 (19.54%) occurred while fishing; of these, 79% were male patients who ranged in age from 6 to 68 years (mean, 37 years). Corneal laceration, globe rupture, and hyphema were the most common diagnoses at presentation and were caused by fishing hooks, lures, and weights. Thirty-five bystanders are included in the study. Thirty-eight percent of patients had visual acuity less than 20/50, and 21% had a visual acuity of less than 20/200. Open globe injuries portended a poor visual outcome compared with closed globe injuries. CONCLUSIONS: Fishing-related ocular injuries represent a large percent of sports-related trauma, often resulting in significant visual loss. Preventive measures such as the use of protective eyewear should be advised in this activity.

Experimental intraoperative use of perfluorotributylamine, perfluorodecaline, and perfluoropolyether

Perfluorocarbonos líquidos (PFCLs) säo compostos com uma gravidade específica maior que a água e utilizados como adjuntos no tratamento cirúrgico de casos complicados de descolamento de retina. 32 coelhos pigmentados foram submetidos a vitrectomia com injeçäo de PFCL dentro da cavidade vítrea: 8 receberam perfluorotributilamino (PFTA); 8 receberam perfluorodecalino (PFDC); 8 receberam perfluoropoliéter (PFPE); os restantes 8 olhos que serviram de controle, receberam soluçäo salina. Uma hora depois das injeçöes foi realizada troca PFCL/soluçäo salina. Os animais foram entäo sacrificados, os olhos enucleados e processados para exames histológicos. A microscopia óptica nenhuma diferença significativa foi demonstrada entre os olhos com PFCLs comparando com os controles. A microscopia óptica nenhuma diferença significativa foi demonstrada entre os olhos com PFCLs comparado com os controles. A microscopia eletrônica revelou somente pequenas alteraçöes, consistindo de alguns defeitos irregulares na forma dos segmentos externos dos fotorreceptores no grupo do PFTA, PFPE e PFDC, pelo menos em nosso modelo animal, näo é associado com nenhuma patologia retiniana significativa